HDFC Pharma & Healthcare Growth Direct Plan
SIP amount
Min. ₹100
Lumpsum amount
Min. ₹100

HDFC Pharma & Healthcare Growth Direct Plan

NAV
₹15.9170
+2.91%
(29 Jan)
AUM
1,577 Cr
TER
0.91%
Risk
Very High Risk
Insights
Net Asset Value (NAV) is above its 200 days moving average
In beta. Send feedback here.
Compare with other fund
1Y
+30.9%
+15.9%
+11.8%
+8.0%
+1.1%
3Y
NA
+28.8%
+28.8%
+30.1%
+28.7%
5Y
NA
+28.5%
+24.6%
+23.3%
+26.3%
ALL
+39.5%
+17.1%
+16.4%
+11.4%
+25.5%
VOL
13.2%
18.1%
19.7%
20.3%
22.7%
TER
0.9%
1.2%
0.8%
0.8%
0.6%
AUM
₹1,577 Cr
₹6,911 Cr
₹1,286 Cr
₹4,572 Cr
₹5,237 Cr
INFO
2.99
0.94
0.83
0.56
1.12
Past performance
Past performance is no guarantee of future returns.
Had you invested
Over the last
1Y
3Y
ALL
Your returns would have been
HDFC Pharma & Healthcare (G)
₹1,00,00,00,000
14.0%
Fixed deposit
₹40,00,00,000
6.0%
Bank savings
₹40,00,00,000
3.0%
See fund holdings as of 30th Nov
Top holdings
Sun Pharmaceuticals Industries Ltd
13.5%
Divi's Laboratories Ltd
7.8%
Cipla Ltd
7.7%
Lupin Ltd
5.8%
Gland Pharma Ltd
4.0%
Ipca Laboratories Ltd
3.7%
Aster DM Healthcare Ltd Ordinary Shares
3.6%
Vijaya Diagnostic Centre Ltd
3.5%
Eris Lifesciences Ltd Registered Shs
3.4%
Glenmark Pharmaceuticals Ltd
3.4%
Top industry exposure
Healthcare
95.2%
Basic Materials
2.0%
Other information
Minimum SIP
₹100
Minimum lumpsum
₹100
Additional lumpsum
₹100
Portfolio turnover
5151%
Lock-in period
-
Exit load
• 1% for redemption within 30 days
Fund objective
To provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies. There is no assurance that the investment objective of the Scheme will be realized.
Fund manager(s)
Dhruv Muchhal
Nikhil Mathur

FAQs